You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNimodipine
Accession NumberDB00393  (APRD00612)
TypeSmall Molecule
GroupsApproved
DescriptionNimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Structure
Thumb
Synonyms
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester
BAY e 9736
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Nimodipine
Nimodipino
Nimodipinum
Nimotop
Periplum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NimotopTablet30 mgOralBayer Inc2009-07-24Not applicableCanada
Nimotop - Cap 30mgCapsule30 mgOralBayer Inc1989-12-312009-08-06Canada
Nimotop Cap 30mgCapsule30 mgOralMiles Canada Inc. Pharmaceutical Division1989-12-311996-10-02Canada
Nimotop I.V.-0.2mg/mlLiquid.2 mgIntravenousBayer Inc1996-10-082000-09-19Canada
Nimotop IV 0.2mg/mlLiquid0.2 mgIntravenousMiles Canada Inc. Pharmaceutical Division1992-12-312000-08-01Canada
NymalizeSolution60 mg/20mLOralArbor Pharmaceuticals2013-06-03Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NimodipineCapsule, liquid filled30 mg/1OralCardinal Health2008-03-21Not applicableUs
NimodipineCapsule, liquid filled30 mg/1OralHeritage2008-03-21Not applicableUs
NimodipineCapsule30 mg/1OralANI Pharmaceuticals, Inc.2015-11-01Not applicableUs
NimodipineCapsule, liquid filled30 mg/1OralMajor Pharmaceuticals2015-01-01Not applicableUs
NimodipineCapsule30 mg/1OralCardinal Health2007-06-28Not applicableUs
NimodipineCapsule, liquid filled30 mg/1OralAscend Laboratories, LLC2015-01-01Not applicableUs
NimodipineCapsule30 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2007-06-28Not applicableUs
NimodipineCapsule, liquid filled30 mg/1OralAmerican Health Packaging2015-02-15Not applicableUs
NimodipineCapsule, liquid filled30 mg/1OralGolden State Medical Supply, Inc.2008-03-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PeriplumNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII57WA9QZ5WH
CAS number66085-59-4
WeightAverage: 418.4403
Monoisotopic: 418.174001196
Chemical FormulaC21H26N2O7
InChI KeyUIAGMCDKSXEBJQ-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
IUPAC Name
3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
Pharmacology
IndicationFor use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
Structured Indications
PharmacodynamicsNimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.
Mechanism of actionAlthough the precise mechanism of action is not known, nimodipine blocks intracellular influx of calcium through voltage-dependent and receptor-operated slow calcium channels across the membranes of myocardial, vascular smooth muscle, and neuronal cells. Nimodipine binds specifically to L-type voltage-gated calcium channels. The inhibition of calcium ion transfer results in the inhibition of vascular smooth muscle contraction. Evidence suggests that the dilation of small cerebral resistance vessels, with a resultant increase in collateral circulation, and/or a direct effect involving the prevention of calcium overload in neurons may be responsible for nimodipine's clinical effect in patients with subarachnoid hemorrhage.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1FProteinyes
inhibitor
HumanO60840 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
Voltage-dependent L-type calcium channel subunit beta-1Proteinyes
inhibitor
HumanQ02641 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit beta-3Proteinyes
inhibitor
HumanP54284 details
Voltage-dependent L-type calcium channel subunit beta-4Proteinyes
inhibitor
HumanO00305 details
Mineralocorticoid receptorProteinunknown
antagonist
HumanP08235 details
Aryl hydrocarbon receptorProteinunknown
agonist
HumanP35869 details
Related Articles
AbsorptionIn humans, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. Bioavailability is 100% following intravenous administration and 3-30% following oral administration due to extensive first-pass metabolism.
Volume of distributionNot Available
Protein binding95% bound to plasma protein
Metabolism

Hepatic metabolism via CYP 3A4.

Route of eliminationNimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug. Numerous metabolites, all of which are either inactive or considerably less active than the parent compound, have been identified.
Half life1.7-9 hours
ClearanceNot Available
ToxicitySymptoms of overdosage would be expected to be related to cardiovascular effects such as excessive peripheral vasodilation with marked systemic hypotension.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nimodipine Action PathwayDrug actionSMP00380
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nimodipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nimodipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nimodipine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nimodipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nimodipine is combined with Aliskiren.Approved, Investigational
AlprazolamThe serum concentration of Nimodipine can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololNimodipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanNimodipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNimodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Nimodipine can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Nimodipine can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nimodipine.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nimodipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimodipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nimodipine is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nimodipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nimodipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nimodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nimodipine.Approved, Investigational
ArmodafinilThe serum concentration of Nimodipine can be decreased when it is combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Nimodipine can be decreased when it is combined with Artemether.Approved
AtazanavirThe serum concentration of Nimodipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nimodipine.Approved
AtomoxetineThe serum concentration of Nimodipine can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Nimodipine can be increased when it is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Atosiban.Approved
Atracurium besylateNimodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nimodipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nimodipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nimodipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nimodipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nimodipine.Approved
BepridilNimodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nimodipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nimodipine.Approved
BexaroteneThe serum concentration of Nimodipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Nimodipine can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nimodipine.Approved
BimatoprostNimodipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Nimodipine can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Nimodipine can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nimodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nimodipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Nimodipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bupivacaine.Approved, Investigational
BupranololNimodipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nimodipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nimodipine.Approved
CalcitriolThe serum concentration of Nimodipine can be decreased when it is combined with Calcitriol.Approved, Nutraceutical
CalciumThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimodipine.Withdrawn
CandoxatrilNimodipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Captopril.Approved
CarbamazepineThe serum concentration of Nimodipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carbetocin.Approved
CarbomycinThe metabolism of Nimodipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nimodipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimodipine.Approved
CeliprololNimodipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nimodipine can be increased when it is combined with Ceritinib.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nimodipine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nimodipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nimodipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimodipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Nimodipine can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Nimodipine can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Nimodipine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Nimodipine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Nimodipine can be increased when it is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.Approved
ClobazamThe serum concentration of Nimodipine can be decreased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Nimodipine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clozapine.Approved
CobicistatThe serum concentration of Nimodipine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Nimodipine can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimodipine.Investigational
CrizotinibThe serum concentration of Nimodipine can be increased when it is combined with Crizotinib.Approved
CryptenamineNimodipine may increase the hypotensive activities of Cryptenamine.Approved
CyclosporineThe serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Nimodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideNimodipine may increase the hypotensive activities of Cyclothiazide.Approved
DabrafenibThe serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe serum concentration of Nimodipine can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Nimodipine can be increased when it is combined with Danazol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nimodipine.Investigational
DarunavirThe serum concentration of Nimodipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Nimodipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinNimodipine may increase the hypotensive activities of Debrisoquin.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nimodipine.Experimental
DeferasiroxThe serum concentration of Nimodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Nimodipine can be increased when it is combined with Delavirdine.Approved
DeserpidineNimodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Desflurane.Approved
DesvenlafaxineThe serum concentration of Nimodipine can be decreased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Nimodipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nimodipine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Diclofenamide.Approved
DicloxacillinThe serum concentration of Nimodipine can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DihydralazineNimodipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Nimodipine can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Nimodipine can be increased when it is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dipyridamole.Approved
DorzolamideNimodipine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Doxazosin.Approved
DoxycyclineThe serum concentration of Nimodipine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Nimodipine can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Nimodipine can be decreased when it is combined with Drospirenone.Approved
DuloxetineNimodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nimodipine.Approved
EfavirenzThe serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nimodipine.Approved
EfonidipineNimodipine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Enalapril.Approved, Vet Approved
EnalaprilatNimodipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Eplerenone.Approved
EpoprostenolNimodipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Eprosartan.Approved
ErythromycinThe serum concentration of Nimodipine can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Nimodipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nimodipine.Approved
EstradiolThe serum concentration of Nimodipine can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.Approved
EtravirineThe serum concentration of Nimodipine can be decreased when it is combined with Etravirine.Approved
ExemestaneThe serum concentration of Nimodipine can be decreased when it is combined with Exemestane.Approved, Investigational
FelbamateThe serum concentration of Nimodipine can be decreased when it is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Felodipine.Approved, Investigational
FenoldopamNimodipine may increase the hypotensive activities of Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Nimodipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nimodipine.Approved
FluoxetineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe serum concentration of Nimodipine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Nimodipine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nimodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Nimodipine can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nimodipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nimodipine can be increased when it is combined with Fusidic Acid.Approved
Glycerol PhenylbutyrateThe serum concentration of Nimodipine can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nimodipine.Experimental
GriseofulvinThe serum concentration of Nimodipine can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuanabenzNimodipine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nimodipine.Approved
GuanethidineNimodipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Guanfacine.Approved, Investigational
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimodipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Halothane.Approved, Vet Approved
HexamethoniumNimodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nimodipine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Nimodipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nimodipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Nimodipine can be decreased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideNimodipine may increase the hypotensive activities of Hydroflumethiazide.Approved
IdelalisibThe serum concentration of Nimodipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of Nimodipine can be increased when it is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Nimodipine.Approved, Investigational
ImatinibThe serum concentration of Nimodipine can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Indapamide.Approved
IndenololNimodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nimodipine can be increased when it is combined with Indinavir.Approved
IndoraminNimodipine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nimodipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nimodipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Nimodipine can be decreased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nimodipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nimodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe serum concentration of Nimodipine can be increased when it is combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Nimodipine can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Nimodipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nimodipine can be increased when it is combined with Ivacaftor.Approved
JosamycinThe metabolism of Nimodipine can be decreased when combined with Josamycin.Approved
KetanserinNimodipine may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Nimodipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Nimodipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Nimodipine is combined with Labetalol.Approved
LacidipineNimodipine may increase the hypotensive activities of Lacidipine.Approved
LapatinibThe serum concentration of Nimodipine can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostNimodipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineNimodipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Levobupivacaine.Approved
LevodopaNimodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Lisinopril.Approved, Investigational
LofexidineNimodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Nimodipine can be increased when it is combined with Lomitapide.Approved
LopinavirThe serum concentration of Nimodipine can be increased when it is combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Losartan.Approved
LovastatinThe serum concentration of Nimodipine can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nimodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nimodipine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Nimodipine can be decreased when it is combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Nimodipine can be increased when it is combined with Lurasidone.Approved
MacitentanNimodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNimodipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nimodipine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mecamylamine.Approved
Medroxyprogesterone acetateThe serum concentration of Nimodipine can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Nimodipine.Approved, Nutraceutical, Vet Approved
MethazolamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nimodipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nimodipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nimodipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nimodipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nimodipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nimodipine.Approved, Investigational
MetyraponeThe serum concentration of Nimodipine can be decreased when it is combined with Metyrapone.Approved
MetyrosineNimodipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimodipine.Experimental
MibefradilNimodipine may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimodipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimodipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Nimodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nimodipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Nimodipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nimodipine.Approved
MitotaneThe serum concentration of Nimodipine can be decreased when it is combined with Mitotane.Approved
MivacuriumNimodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nimodipine.Approved
ModafinilThe serum concentration of Nimodipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nimodipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nimodipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Morphine.Approved, Investigational
MoxonidineNimodipine may increase the hypotensive activities of Moxonidine.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nimodipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nadolol.Approved
NafcillinThe metabolism of Nimodipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimodipine.Approved
NaftopidilNimodipine may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nimodipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nimodipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nimodipine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nimodipine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nimodipine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nimodipine.Withdrawn
NicardipineThe serum concentration of Nimodipine can be increased when it is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nimodipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nifedipine.Approved
NiguldipineNimodipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nimodipine can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNimodipine may increase the hypotensive activities of Nilvadipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nisoldipine.Approved
NitrendipineNimodipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNimodipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nimodipine.Approved
NorgestimateThe serum concentration of Nimodipine can be decreased when it is combined with Norgestimate.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimodipine.Approved, Vet Approved
ObinutuzumabNimodipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nimodipine.Withdrawn
OlaparibThe serum concentration of Nimodipine can be increased when it is combined with Olaparib.Approved
OleandomycinThe metabolism of Nimodipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimodipine.Approved, Investigational
OmapatrilatNimodipine may increase the hypotensive activities of Omapatrilat.Investigational
OritavancinThe serum concentration of Nimodipine can be decreased when it is combined with Oritavancin.Approved, Investigational
OsimertinibThe serum concentration of Nimodipine can be increased when it is combined with Osimertinib.Approved
OxcarbazepineThe serum concentration of Nimodipine can be decreased when it is combined with Oxcarbazepine.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimodipine.Approved
OxprenololNimodipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nimodipine.Investigational
PalbociclibThe serum concentration of Nimodipine can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Nimodipine.Approved
PazopanibThe serum concentration of Nimodipine can be increased when it is combined with Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimodipine.Approved
PentobarbitalThe serum concentration of Nimodipine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumNimodipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nimodipine.Approved, Investigational
PerampanelThe serum concentration of Nimodipine can be decreased when it is combined with Perampanel.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nimodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nimodipine.Withdrawn
PhenobarbitalThe serum concentration of Nimodipine can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineNimodipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nimodipine.Withdrawn
PhentolamineNimodipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Nimodipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PinacidilNimodipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Pindolol.Approved
PioglitazoneThe serum concentration of Nimodipine can be decreased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Nimodipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nimodipine.Withdrawn
PolythiazideNimodipine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Nimodipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nimodipine is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Prazosin.Approved
PrednisoneThe serum concentration of Nimodipine can be decreased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Nimodipine can be decreased when it is combined with Primidone.Approved, Vet Approved
PropofolThe serum concentration of Nimodipine can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Nimodipine can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Nimodipine.Approved
QuinupristinThe serum concentration of Nimodipine can be increased when it is combined with Quinupristin.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nimodipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimodipine.Approved
RanolazineThe serum concentration of Nimodipine can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumNimodipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nimodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nimodipine.Approved
RescinnamineNimodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nimodipine.Approved
RifabutinThe serum concentration of Nimodipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Nimodipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nimodipine can be decreased when it is combined with Rifapentine.Approved
RilmenidineNimodipine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nimodipine is combined with Riociguat.Approved
RisperidoneNimodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Nimodipine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabNimodipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Nimodipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Rotigotine.Approved
RufinamideThe serum concentration of Nimodipine can be decreased when it is combined with Rufinamide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nimodipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nimodipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimodipine.Approved, Vet Approved
SaprisartanNimodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Nimodipine can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Nimodipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nimodipine.Approved, Investigational, Vet Approved
SelexipagNimodipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nimodipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Nimodipine can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Nimodipine.Approved
SiltuximabThe serum concentration of Nimodipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nimodipine can be increased when it is combined with Simeprevir.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nimodipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimodipine.Approved, Investigational
SitaxentanNimodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Nimodipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sotalol.Approved
SpiraprilNimodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nimodipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Nimodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nimodipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nimodipine.Approved
SulfisoxazoleThe serum concentration of Nimodipine can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nimodipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nimodipine.Approved, Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Nimodipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nimodipine.Approved
TelaprevirThe serum concentration of Nimodipine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Nimodipine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Telmisartan.Approved, Investigational
TemocaprilNimodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Terazosin.Approved
TerbinafineThe serum concentration of Nimodipine can be decreased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimodipine.Approved
TerlipressinNimodipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Nimodipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nimodipine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Thioridazine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nimodipine.Approved
TiboloneNimodipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Nimodipine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Nimodipine can be increased when it is combined with Ticlopidine.Approved
TicrynafenNimodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nimodipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nimodipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineNimodipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nimodipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nimodipine.Approved
TopiramateThe serum concentration of Nimodipine can be decreased when it is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nimodipine.Approved
TrametinibThe serum concentration of Nimodipine can be decreased when it is combined with Trametinib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nimodipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nimodipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nimodipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nimodipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nimodipine.Approved
TrichlormethiazideNimodipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinNimodipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanNimodipine may increase the hypotensive activities of Trimethaphan.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimodipine.Approved, Investigational
TroleandomycinThe metabolism of Nimodipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Nimodipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Nimodipine.Approved, Investigational
UnoprostoneNimodipine may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimodipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nimodipine.Approved
VemurafenibThe serum concentration of Nimodipine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Nimodipine can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.Approved
VinpocetineNimodipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Nimodipine can be increased when it is combined with Voriconazole.Approved, Investigational
XylometazolineNimodipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nimodipine.Approved, Vet Approved
ZiprasidoneThe serum concentration of Nimodipine can be increased when it is combined with Ziprasidone.Approved
Food Interactions
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nimodipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nimodipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take at the same time each day, with or without food, but always in the same manner.
References
Synthesis ReferenceNot Available
General References
  1. Janjua N, Mayer SA: Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care. 2003 Apr;9(2):113-9. [PubMed:12657973 ]
  2. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR: Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983 Mar 17;308(11):619-24. [PubMed:6338383 ]
  3. Belfort MA, Anthony J, Saade GR, Allen JC Jr: A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003 Jan 23;348(4):304-11. [PubMed:12540643 ]
  4. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  5. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F: Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens. 2008 Nov;30(8):744-66. doi: 10.1080/10641960802580232. [PubMed:19021025 ]
  6. Vergouwen MD, Vermeulen M, Roos YB: Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review. Lancet Neurol. 2006 Dec;5(12):1029-32. [PubMed:17110283 ]
External Links
ATC CodesC08CA06
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (504 KB)
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9387
Blood Brain Barrier-0.9358
Caco-2 permeable-0.5838
P-glycoprotein substrateSubstrate0.752
P-glycoprotein inhibitor IInhibitor0.9287
P-glycoprotein inhibitor IIInhibitor0.9098
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8151
CYP450 2D6 substrateNon-substrate0.9118
CYP450 3A4 substrateSubstrate0.7571
CYP450 1A2 substrateInhibitor0.9108
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.8248
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.5976
CarcinogenicityNon-carcinogens0.6953
BiodegradationNot ready biodegradable0.8797
Rat acute toxicity2.5326 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6468
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Barr laboratories inc
  • Sun pharmaceutical industries inc
  • Bayer pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg/1
Capsule, liquid filledOral30 mg/1
TabletOral30 mg
CapsuleOral30 mg
LiquidIntravenous.2 mg
LiquidIntravenous0.2 mg
SolutionOral60 mg/20mL
Prices
Unit descriptionCostUnit
NiMODipine 100 30 mg capsule Box952.07USD box
Nimotop 30 mg capsule9.87USD capsule
Nimodipine 30 mg capsule9.69USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point125 °CNot Available
logP3.05MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.41ALOGPS
logP2.54ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)5.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area119.68 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity112.38 m3·mol-1ChemAxon
Polarizability43.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Ether
  • Enamine
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Marchetti C, Usai C: High affinity block by nimodipine of the internal calcium elevation in chronically depolarized rat cerebellar granule neurons. Neurosci Lett. 1996 Mar 29;207(2):77-80. [PubMed:8731425 ]
  3. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  4. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  5. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  6. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  7. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
  8. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
  2. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  3. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  4. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  5. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  6. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
  2. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  3. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  4. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  5. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  6. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
  6. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB3
Uniprot ID:
P54284
Molecular Weight:
54531.425 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB4
Uniprot ID:
O00305
Molecular Weight:
58168.625 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. [PubMed:18250364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transcription regulatory region dna binding
Specific Function:
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and matu...
Gene Name:
AHR
Uniprot ID:
P35869
Molecular Weight:
96146.705 Da
References
  1. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007 Jun;71(6):1475-86. Epub 2007 Feb 27. [PubMed:17327465 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23